Abstract
Nicotine dependence has progressively become a foremost community health interest in both the developed and developing nations due to the economic burden and health-related problems. Smoking was significantly higher among patients with schizophrenia in comparison to the general population. Nicotine dependence is not only associated with public stress, but among patients with schizophrenia, smoking brings major challenges to the management. Nicotine may diminish the therapeutic efficacy of the bioavailability of the psychopharmacological agents in-vivo. These duo perturbations, i.e. two clinical conditions co-existed may prevent psychotic symptoms remission among patients suffering from schizophrenia who smoke at the same time. The aim of this review was to highlight the role of pharmacological treatment options and strategies for patients with nicotine dependence in schizophrenia with emphasis on the underlying neurobiological process. The role of nicotine replacement therapy, i.e. norepinephrine-dopamine reuptake inhibition (NDRI) e.g. bupropion and selective partial agonist of α4β2 and full α7-nicotinic acetylcholine receptor e.g. varenicline was deliberated. An ideal choice of drug targets for patients with schizophrenia with nicotine dependence is pivotal to foster a better therapeutic alliance.
| Original language | English |
|---|---|
| Pages (from-to) | 173-181 |
| Number of pages | 9 |
| Journal | Current Drug Targets |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Jan 2019 |
Fingerprint
Keywords
- drug targets
- Nicotine dependence
- psychoactive agents
- schizophrenia
- smoking
- treatment options.
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Clinical Biochemistry
Cite this
Schizophrenia and Nicotine Dependence : What Psychopharmacological Treatment Options are Available for the Duo Perturbationes? / Theng, Yoong Mei; Wahab, Suzaily; Abdul Wahab, Noor Alaudin; Sidi, Hatta; Das, Srijit.
In: Current Drug Targets, Vol. 20, No. 2, 01.01.2019, p. 173-181.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Schizophrenia and Nicotine Dependence
T2 - What Psychopharmacological Treatment Options are Available for the Duo Perturbationes?
AU - Theng, Yoong Mei
AU - Wahab, Suzaily
AU - Abdul Wahab, Noor Alaudin
AU - Sidi, Hatta
AU - Das, Srijit
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Nicotine dependence has progressively become a foremost community health interest in both the developed and developing nations due to the economic burden and health-related problems. Smoking was significantly higher among patients with schizophrenia in comparison to the general population. Nicotine dependence is not only associated with public stress, but among patients with schizophrenia, smoking brings major challenges to the management. Nicotine may diminish the therapeutic efficacy of the bioavailability of the psychopharmacological agents in-vivo. These duo perturbations, i.e. two clinical conditions co-existed may prevent psychotic symptoms remission among patients suffering from schizophrenia who smoke at the same time. The aim of this review was to highlight the role of pharmacological treatment options and strategies for patients with nicotine dependence in schizophrenia with emphasis on the underlying neurobiological process. The role of nicotine replacement therapy, i.e. norepinephrine-dopamine reuptake inhibition (NDRI) e.g. bupropion and selective partial agonist of α4β2 and full α7-nicotinic acetylcholine receptor e.g. varenicline was deliberated. An ideal choice of drug targets for patients with schizophrenia with nicotine dependence is pivotal to foster a better therapeutic alliance.
AB - Nicotine dependence has progressively become a foremost community health interest in both the developed and developing nations due to the economic burden and health-related problems. Smoking was significantly higher among patients with schizophrenia in comparison to the general population. Nicotine dependence is not only associated with public stress, but among patients with schizophrenia, smoking brings major challenges to the management. Nicotine may diminish the therapeutic efficacy of the bioavailability of the psychopharmacological agents in-vivo. These duo perturbations, i.e. two clinical conditions co-existed may prevent psychotic symptoms remission among patients suffering from schizophrenia who smoke at the same time. The aim of this review was to highlight the role of pharmacological treatment options and strategies for patients with nicotine dependence in schizophrenia with emphasis on the underlying neurobiological process. The role of nicotine replacement therapy, i.e. norepinephrine-dopamine reuptake inhibition (NDRI) e.g. bupropion and selective partial agonist of α4β2 and full α7-nicotinic acetylcholine receptor e.g. varenicline was deliberated. An ideal choice of drug targets for patients with schizophrenia with nicotine dependence is pivotal to foster a better therapeutic alliance.
KW - drug targets
KW - Nicotine dependence
KW - psychoactive agents
KW - schizophrenia
KW - smoking
KW - treatment options.
UR - http://www.scopus.com/inward/record.url?scp=85060018010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060018010&partnerID=8YFLogxK
U2 - 10.2174/1389450118666171017163741
DO - 10.2174/1389450118666171017163741
M3 - Article
C2 - 29046149
AN - SCOPUS:85060018010
VL - 20
SP - 173
EP - 181
JO - Current Drug Targets
JF - Current Drug Targets
SN - 1389-4501
IS - 2
ER -